The DC Cohort Longitudinal HIV Status Neutral Study (NCT01206920) | Clinical Trial Compass
RecruitingNot Applicable
The DC Cohort Longitudinal HIV Status Neutral Study
United States19,000 participantsStarted 2011-01
Plain-language summary
The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes, and improve the quality of care for patients diagnosed with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) or at higher risk for acquiring HIV and receiving care in Washington, DC.
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Treatment Cohort Inclusion Criteria:
* Patient is receiving care for HIV at one or more of the twelve participating clinics in the DC Cohort.
* Patient is either age 18 years or older, or seeks HIV care independently and is able to understand and sign informed consent.
* Patient is a minor who is consented by a parent or legal guardian.
Treatment Cohort Exclusion Criteria:
* Patient is unable or refuses to provide informed consent.
* Minor children ages 12 through 17 who are unaware of their HIV status
Prevention Cohort Inclusion Criteria:
Persons receiving any antiretroviral prescription without evidence of HIV or Hepatitis B infection
* PrEP (e.g., TDF/FTC, Descovy, Apretude)
* Combination ART indicative of nPEP in an HIV-uninfected person
* Persons receiving an antiretroviral prescription indicative of DoxyPEP Doxycycline 200mg PO taken within 72 hrs of unprotected sexual encounter (or variations thereof where clearly not prescribed as a treatment course)
* Test positive for ≥1 bacterial STI (positive gonorrhea (GC/NG) or chlamydia (CT) test or positive syphilis test requiring treatment within one year)
* 2 bacterial STI (GC, chlamydia, syphilis) tests at 2 or more different encounters
* 2 HIV tests at 2 or more different encounters
* Patient requesting PrEP at their clinical visit
* Patient requesting nPEP at their clinical visit
* People who identify as injecting drugs
Patients with a Z29.81 Encounter for HIV pre-exposure prophylaxis
What they're measuring
1
viral suppression among persons with HIV
Timeframe: through study completion, an average of 10 years from enrollment to the end of study follow up
2
clinical outcomes persons at higher risk for acquiring HIV
Timeframe: through study completion, an average of 5 years from enrollment to the end of study follow up period